The hospital at home in the USA: current status and future prospects.

Publication date: Feb 27, 2024

The annual cost of hospital care services in the US has risen to over $1 trillion despite relatively worse health outcomes compared to similar nations. These trends accentuate a growing need for innovative care delivery models that reduce costs and improve outcomes. HaH-a program that provides patients acute-level hospital care at home-has made significant progress over the past two decades. Technological advancements in remote patient monitoring, wearable sensors, health information technology infrastructure, and multimodal health data processing have contributed to its rise across hospitals. More recently, the COVID-19 pandemic brought HaH into the mainstream, especially in the US, with reimbursement waivers that made the model financially acceptable for hospitals and payors. However, HaH continues to face serious challenges to gain widespread adoption. In this review, we evaluate the peer-reviewed evidence and discuss the promises, challenges, and what it would take to tap into the future potential of HaH.

Open Access PDF

Concepts Keywords
Decades Annual
Home Care
Hospitals Cost
Pandemic Current
Technological Future
Home
Hospital
Hospitals
Outcomes
Prospects
Risen
Services
Status
Usa
Worse

Semantics

Type Source Name
disease VO USA
disease MESH COVID-19 pandemic
drug DRUGBANK Etodolac
disease MESH nosocomial infection
disease MESH complications
disease VO efficient
disease MESH critically ill
disease VO effectiveness
disease IDO intervention
drug DRUGBANK Etoperidone
disease IDO site
disease MESH pneumonia
disease MESH heart failure
disease MESH COPD
disease MESH cellulitis
disease MESH emergency
disease VO frequency
disease MESH urinary tract infection
disease IDO blood
disease IDO quality
disease VO device
disease MESH gait
drug DRUGBANK Dextrose unspecified form
pathway REACTOME Vitamins
drug DRUGBANK Lactic Acid
drug DRUGBANK Creatinine
drug DRUGBANK Ethanol
drug DRUGBANK Urea
drug DRUGBANK Levodopa
drug DRUGBANK Hydrocortisone
disease VO time
disease MESH chronic conditions
drug DRUGBANK Coenzyme M
drug DRUGBANK Activated charcoal
disease MESH infections
disease VO effective
disease MESH morbidity
drug DRUGBANK Cysteamine
disease IDO history
drug DRUGBANK Nonoxynol-9
disease VO adverse event
drug DRUGBANK Alpha-1-proteinase inhibitor
drug DRUGBANK Trestolone
disease VO population
drug DRUGBANK Methionine
disease MESH infarction
drug DRUGBANK Isosorbide Mononitrate
disease MESH respiratory tract infection
disease MESH cardiovascular disease
disease MESH Cancer
disease IDO infection
disease VO Equity
disease VO volume
drug DRUGBANK Angiotensin II

Original Article

(Visited 1 times, 1 visits today)